The Latest RoboSense LiDAR Perception Solution Will Support Robo Taxi Development
4.12.2019 17:00:00 EET | Business Wire | Press release
RoboSense today announced its launch of a developed and complete LiDAR perception solution for Robo Taxi (RS-Fusion-P5) in markets outside China. The RS-Fusion-P5 was first launched in China last month. Equipped with an RS-Ruby and four RS-BPearl, The RS-Fusion-P5 is considered to be the alternative to Waymo's LiDAR solution, further accelerating the development of Robo Taxi.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005271/en/
(Graphic: Business Wire)
Full Coverage, Zero Blind Spots In The Range Of 200 Meters
RoboSense RS-Fusion-P5 uses an RS-Ruby on top of the vehicle to ensure a sensing range with a radius of more than 200 meters. However, even if the vertical field of view (FOV) of RS-Ruby reaches the perfect angles from -25° to +15°, there is still a small blind zone around the vehicle body. Therefore, to cover the small blind zone, 4 RS-BPearl embedded sideways around the vehicle form a hemisphere FOV scanning area relative to the vehicle's perspective, to guarantee a complete 360° surrounding view.
Empowers Level 4 Or Above Autonomous Vehicles With Full-stack Perception Capabilities
The RS-Fusion-P5 solution fuses point clouds from RS-Ruby and RS-BPearl in real-time, and generate laser points of more than 4,600,000pts per second.
Through its advanced AI perception algorithms, multi-sensor fusion and synchronization interfaces, vehicles are able to identify all-around obstacles and position easily and precisely.
The Main RS-Ruby With 0.1 ° Vertical Resolution, 200m @ 10% Ranging Ability
RS-Ruby achieves the anti-interference of multiple LiDAR using special laser encryption technology to filter interference signals. Meanwhile, it is not affected by the strongest direct-sunlight. Its LiDAR reflection intensity reaches a perfect balance of consistency and distinction.
RS-BPearl Reaches The Minimum Detection Range Of Less Than 5cm
The embedded four RS-BPearl form a hemispherical FOV coverage of 90 ° * 360 °, which not only can precisely identify objects around the vehicle body such as pets, children, roadbeds as well as other details of the near-field ground area, but also detect the actual height information under particular scenarios such as bridge tunnels and culverts, further supporting autonomous vehicles for driving decision making and greatly improving car safety.
The RS-Fusion-P5 is able to reach 200m detection range, 0.1° high-precision resolution with full coverage, zero blind spots in the sensing zone. It is one of the leading and developed automotive LiDAR solution for Robo Taxi available on the market. More details of RS-Fusion-P5 can be found at http://www.robosense.cn/rslidar/rs-fusion-p5.
Meanwhile, RoboSense wins CES 2020 Innovation Award for autonomous vehicle technology, and will be exhibiting at booth 6138, LVCC North Hall, CES 2020 from Jan. 7 – 10, 2020, and tabletop No. 602 at CES Unveiled Las Vegas, on Jan. 5, 2020, 5 – 8:30 p.m. PST.
About RoboSense:
The world’s leading autonomous driving LiDAR perception solution provider, RoboSense, supplies LiDAR technologies to a wide range of domestic and international autonomous driving technology companies, OEMs, and tier 1 suppliers. RoboSense technologies are widely used in autonomous driving logistics vehicles, buses, and passenger cars, with partners including SAIC, BAIC, Baidu, Cainiao Network, JD.com, ControlWorks, Aidrivers, and more. In China, RoboSense has received more than 300 million RMB in strategic investments from Alibaba’s Cainiao Network, SAIC, and BAIC, making RoboSense Asia’s number one LiDAR company, with the largest funding in China’s LiDAR industry. RoboSense has won numerous international awards, including the CES 2020 and 2019 Innovation Awards, the 2019 AutoSens Award, and the 2019 Stevie Award - Gold Award. For more information on RoboSense, see the website at http://www.robosense.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005271/en/
Contact information
Media:
Cassie Gong
RoboSense PR Manager
sqgong@robosense.cn
86-18620031448
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
